Advertisement
Screener

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Increase (Decrease) in Other Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Other Accrued Liabilities

ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Other Accrued Liabilities of $36.35 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2019-10-31

  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2019-09-30 was $34.92M, a 94.21% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2019-06-30 was $16.16M, a 15.08% decline year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2019-03-31 was -$14.73M.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for the quarter ending 2018-12-31 was $34.12M, a 33.38% increase year-over-year.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2018 was $59.36M, a 88.03% increase from fiscal 2017.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2017 was $31.57M, a 195.77% increase from fiscal 2016.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2016 was $10.67M, a 68.26% increase from fiscal 2015.
  • ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in other accrued liabilities for fiscal 2015 was $6.34M, a 30.46% decline from fiscal 2014.
Period endIncrease (Decrease) in Other Accrued Liabilities 3 monthIncrease (Decrease) in Other Accrued Liabilities 6 monthIncrease (Decrease) in Other Accrued Liabilities 9 monthIncrease (Decrease) in Other Accrued Liabilities 12 month
2019-09-30$34.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$51.08M
derived: sum of 2 quarters · filed 2019-10-31
$36.35M
10-Q · filed 2019-10-31
$70.46M
derived: sum of 4 quarters · filed 2019-10-31
2019-06-30$16.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$1.43M
10-Q · filed 2019-08-06
$35.54M
derived: sum of 3 quarters · filed 2019-08-06
$53.52M
derived: sum of 4 quarters · filed 2019-10-31
2019-03-31-$14.73M
10-Q · filed 2019-05-02
$19.38M
derived: sum of 2 quarters · filed 2019-05-02
$37.37M
derived: sum of 3 quarters · filed 2019-10-31
$56.39M
derived: sum of 4 quarters · filed 2019-10-31
2018-12-31$34.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14
$52.10M
derived: sum of 2 quarters · filed 2019-10-31
$71.12M
derived: sum of 3 quarters · filed 2019-10-31
$59.36M
10-K · filed 2019-02-14
2018-09-30$17.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$37.01M
derived: sum of 2 quarters · filed 2019-10-31
$25.24M
10-Q · filed 2019-10-31
$50.82M
derived: sum of 4 quarters · filed 2019-10-31
2018-06-30$19.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
$7.26M
10-Q · filed 2019-08-06
$32.84M
derived: sum of 3 quarters · filed 2019-08-06
$42.23M
derived: sum of 4 quarters · filed 2019-08-06
2018-03-31-$11.77M
10-Q · filed 2019-05-02
$13.81M
derived: sum of 2 quarters · filed 2019-05-02
$23.20M
derived: sum of 3 quarters · filed 2019-05-02
$30.66M
derived: sum of 4 quarters · filed 2019-05-02
2017-12-31$25.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14
$34.97M
derived: sum of 2 quarters · filed 2019-02-14
$42.42M
derived: sum of 3 quarters · filed 2019-02-14
$31.57M
10-K · filed 2019-02-14
2017-09-30$9.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$16.84M
derived: sum of 2 quarters · filed 2018-11-07
$5.99M
10-Q · filed 2018-11-07
$9.91M
derived: sum of 4 quarters · filed 2019-02-14
2017-06-30$7.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
-$3.40M
10-Q · filed 2018-08-02
$520.00K
derived: sum of 3 quarters · filed 2019-02-14
$5.55M
derived: sum of 4 quarters · filed 2019-02-14
2017-03-31-$10.86M
10-Q · filed 2018-05-04
-$6.93M
derived: sum of 2 quarters · filed 2019-02-14
-$1.90M
derived: sum of 3 quarters · filed 2019-02-14
$4.12M
derived: sum of 4 quarters · filed 2019-02-14
2016-12-31$3.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14
$8.96M
derived: sum of 2 quarters · filed 2019-02-14
$14.98M
derived: sum of 3 quarters · filed 2019-02-14
$10.67M
10-K · filed 2019-02-14
2016-09-30$5.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$11.05M
derived: sum of 2 quarters · filed 2017-11-07
$6.75M
10-Q · filed 2017-11-07
$17.57M
derived: sum of 4 quarters · filed 2018-02-15
2016-06-30$6.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$1.72M
10-Q · filed 2017-08-09
$12.54M
derived: sum of 3 quarters · filed 2018-02-15
$14.97M
derived: sum of 4 quarters · filed 2018-02-15
2016-03-31-$4.30M
10-Q · filed 2017-05-05
$6.51M
derived: sum of 2 quarters · filed 2018-02-15
$8.95M
derived: sum of 3 quarters · filed 2018-02-15
$10.47M
derived: sum of 4 quarters · filed 2018-02-15
2015-12-31$10.82M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15
$13.25M
derived: sum of 2 quarters · filed 2018-02-15
$14.78M
derived: sum of 3 quarters · filed 2018-02-15
$6.34M
10-K · filed 2018-02-15
2015-09-30$2.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$3.96M
derived: sum of 2 quarters · filed 2016-11-03
-$4.47M
10-Q · filed 2016-11-03
-$2.64M
derived: sum of 4 quarters · filed 2017-02-15
2015-06-30$1.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
-$6.91M
10-Q · filed 2016-08-04
-$5.08M
derived: sum of 3 quarters · filed 2017-02-15
-$22.00K
derived: sum of 4 quarters · filed 2017-02-15
2015-03-31-$8.43M
10-Q · filed 2016-05-04
-$6.60M
derived: sum of 2 quarters · filed 2017-02-15
-$1.54M
derived: sum of 3 quarters · filed 2017-02-15
-$3.08M
derived: sum of 4 quarters · filed 2017-02-15
2014-12-31$1.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15
$6.89M
derived: sum of 2 quarters · filed 2017-02-15
$5.35M
derived: sum of 3 quarters · filed 2017-02-15
$9.12M
10-K · filed 2017-02-15
2014-09-30$5.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$3.52M
derived: sum of 2 quarters · filed 2015-11-09
$7.29M
10-Q · filed 2015-11-09
$4.97M
derived: sum of 4 quarters · filed 2016-02-12
2014-06-30-$1.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07
$2.23M
10-Q · filed 2015-08-07
-$89.00K
derived: sum of 3 quarters · filed 2016-02-12
$6.83M
derived: sum of 4 quarters · filed 2016-02-12
2014-03-31$3.77M
10-Q · filed 2015-05-08
$1.45M
derived: sum of 2 quarters · filed 2016-02-12
$8.36M
derived: sum of 3 quarters · filed 2016-02-12
$7.11M
derived: sum of 4 quarters · filed 2016-02-12
2013-12-31-$2.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12
$4.59M
derived: sum of 2 quarters · filed 2016-02-12
$3.34M
derived: sum of 3 quarters · filed 2016-02-12
$1.55M
10-K · filed 2016-02-12
2013-09-30$6.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
$5.66M
derived: sum of 2 quarters · filed 2014-11-06
$3.87M
10-Q · filed 2014-11-06
-$2.40M
derived: sum of 4 quarters · filed 2015-02-13
2013-06-30-$1.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08
-$3.04M
10-Q · filed 2014-08-08
-$9.31M
derived: sum of 3 quarters · filed 2015-02-13
-$9.22M
derived: sum of 4 quarters · filed 2015-02-13
2013-03-31-$1.79M
10-Q · filed 2014-05-09
-$8.06M
derived: sum of 2 quarters · filed 2015-02-13
-$7.97M
derived: sum of 3 quarters · filed 2015-02-13
-$5.63M
derived: sum of 4 quarters · filed 2015-02-13
2012-12-31-$6.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13
-$6.18M
derived: sum of 2 quarters · filed 2015-02-13
-$3.84M
derived: sum of 3 quarters · filed 2015-02-13
-$3.59M
10-K · filed 2015-02-13
2012-09-30$91.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07
$2.43M
derived: sum of 2 quarters · filed 2013-11-07
$2.68M
10-Q · filed 2013-11-07
$3.39M
derived: sum of 4 quarters · filed 2014-02-20
2012-06-30$2.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
$2.59M
10-Q · filed 2013-08-09
$3.30M
derived: sum of 3 quarters · filed 2014-02-20
$4.13M
derived: sum of 4 quarters · filed 2014-02-20
2012-03-31$252.00K
10-Q · filed 2013-05-07
$968.00K
derived: sum of 2 quarters · filed 2014-02-20
$1.80M
derived: sum of 3 quarters · filed 2014-02-20
$929.00K
derived: sum of 4 quarters · filed 2014-02-20
2011-12-31$716.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20
$1.55M
derived: sum of 2 quarters · filed 2014-02-20
$677.00K
derived: sum of 3 quarters · filed 2014-02-20
$2.46M
10-K · filed 2014-02-20
2011-09-30$831.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05
-$39.00K
derived: sum of 2 quarters · filed 2012-11-05
$1.74M
10-Q · filed 2012-11-05
$1.84M
derived: sum of 4 quarters · filed 2013-02-19
2011-06-30-$870.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08
$910.00K
10-Q · filed 2012-08-08
$1.01M
derived: sum of 3 quarters · filed 2013-02-19
$4.13M
derived: sum of 4 quarters · filed 2013-02-19
2011-03-31$1.78M
10-Q · filed 2012-05-03
$1.88M
derived: sum of 2 quarters · filed 2013-02-19
$5.00M
derived: sum of 3 quarters · filed 2013-02-19
$3.64M
derived: sum of 4 quarters · filed 2013-02-19
2010-12-31$98.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19
$3.22M
derived: sum of 2 quarters · filed 2013-02-19
$1.86M
derived: sum of 3 quarters · filed 2013-02-19
$651.00K
10-K · filed 2013-02-19
2010-09-30$3.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03
$1.76M
derived: sum of 2 quarters · filed 2011-11-03
$553.00K
10-Q · filed 2011-11-03
$1.97M
derived: sum of 4 quarters · filed 2012-02-13
2010-06-30-$1.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03
-$2.57M
10-Q · filed 2011-08-03
-$1.15M
derived: sum of 3 quarters · filed 2012-02-13
-$2.71M
derived: sum of 4 quarters · filed 2012-02-13
2010-03-31-$1.21M
10-Q · filed 2011-05-05
$212.00K
derived: sum of 2 quarters · filed 2012-02-13
-$1.35M
derived: sum of 3 quarters · filed 2012-02-13
2009-12-31$1.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13
-$140.00K
derived: sum of 2 quarters · filed 2012-02-13
-$341.00K
10-K · filed 2012-02-13
2009-09-30-$1.56M
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04
-$1.76M
10-Q · filed 2010-11-04
2009-06-30-$201.00K
10-Q · filed 2010-08-05
2008-12-31-$3.82M
10-K · filed 2011-02-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10